ARCA biopharma

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor.

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review.

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.

ARCA biopharma Announces First Quarter 2022 Financial Results

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value.   The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committee includes ARCA Board Chairman Robert E. Conway (chair), and Board members Linda Grais, M.D. and Anders Hove, M.D.

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the 160-patient trial, both doses of rNAPc2 demonstrated a treatment benefit.

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

WESTMINSTER, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 compared to standard of care heparin.

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022 Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O 2 , a publication of the Hearth Rhythm Society. The paper details an analysis that examined the prevalence of bradycardia and its association with adverse events (AEs) and failure to achieve target dose in the GENETIC-AF Phase 2b clinical trial. In the genetically defined population of GENETIC-AF (all ADRB1 Arg389Arg genotype), the prevalence of clinically important bradycardia was lower for Gencaro compared to metoprolol, with an incidence of heart rate (HR)

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.   160 patients were enrolled at clinical investigative sites in the United States, Argentina and Brazil. The Company anticipates reporting topline data from the clinical trial in the first quarter of 2022.

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Tom Keuer, Chief Operating Officer, will present at the Q4 Virtual Investor Summit being held November 16-17, 2021.

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

WESTMINSTER, Colo., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2021 financial results and provided a corporate update.

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

The Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis for ARCA biopharma Inc's (NASDAQ: ABIO) ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2, a small recombinant protein for COVID-19. Based on the review of approximately 75% of the projected final efficacy and safety data, DSMC recommended completing the trial with no modifications to the trial design.

ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged

WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on the ASPEN-COVID-19 Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with severe COVID-19. The Company announced that the Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis and, based on the DSMC's review of approximately 75% of the projected final efficacy and safety data, recommended completion of the clinical trial with no modifications to the trial design. The rNAPc2 development program has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).   The Company now anticipates completion of target enrollment of 160 patients by year end 2021 and reporting of topline data in the first quarter of 2022.

ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data

WESTMINSTER, Colo., Sept. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. The patient was enrolled in Brazil. ARCA also plans to enroll patients from Argentina and is currently enrolling patients at multiple sites in the United States. The international Phase 2b trial is approximately 75% enrolled as of this date. The Company currently anticipates topline trial data in the fourth quarter of 2021.

ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker, Chief Financial Officer, will present at the Q3 Virtual Investor Summit being held August 17-18, 2021.

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update.

ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., July 13, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.

ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Thomas Keuer, Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021.

ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th

BioDelivery Sciences

Dare Bioscience

G Medical Innovations Holdings Ltd

Jaguar Health

Luokung Technology Corp

Exela Technologies

Are these Reddit penny stocks the best 7 to watch in July 2021? The post Best Reddit Penny Stocks to Buy Now?

Best Reddit Penny Stocks to Buy Now? 7 for Your July Small-Caps List

WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2021 financial results and provided a corporate update.

ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development.

Christopher Graybill Joins ARCA as Vice President, Clinical Development

WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced C. Jeff Dekker as its Chief Financial Officer, effective May 10, 2021, following Brian Selby's planned departure after 14 years of service with the Company.

ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer

WESTMINSTER, Colo., March 18, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2020 financial results and provided a corporate update.

ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update

Athira Pharma

Metacrine

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed the share prices near or above the liquidation value. Should the company fail, these shareholders would, in theory, still be able to make money due to a difference between the liquidation value and purchasing price.

3 Net-Net Working Capital Stocks

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company's offices located at 10170 Church Ranch Way, Suite 100, Westminster, CO 80021, approximately one-quarter mile from the previously noticed location. The meeting location change is due to the COVID-19 related unavailability of the previously noticed meeting location.

News for ARCA biopharma Stock (ABIO)